- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01810354
PROPHYLACTIC ANTIBIOTICS PRIOR TO CESAREAN SECTION IN OBESE WOMEN
PROPHYLACTIC ANTIBIOTICS PRIOR TO CESAREAN SECTION IN OBESE WOMEN: Does Increasing the Dose Increase the Tissue Concentration?
Surgical site infections are common and a cause of major morbidity. They are also more common in obese women. Cesarean sections are the most common surgery performed in the United States, therefore pregnant women are being faced with this problem frequently. There is evidence to show that prophylactically administered antibiotics, cefazolin specifically, to obese women prior to cesarean section do not reach adequate concentrations in adipose tissue to prevent infection. The purpose of this study is to evaluate if an increased dose of cefazolin will attain adequate tissue concentration in obese women. Our hypothesis is that three grams of cefazolin given no more than 60 minutes prior to the start of a cesarean section in an obese (Body mass index (BMI) greater than or equal to 30) woman will attain adequate adipose tissue concentration compared to two grams of cefazolin.
Subjects will be selected if they are greater than 37 weeks gestation wiht a singleton pregnancy and require a cesarean section for any obstetrical indication. Women will be excluded if they have a suspected infection, have a multiple gestation, or have preexisting diabetes or hypertension with end organ damage. The subjects will be screened both by through the OR schedule as well as through the clinics. They will then be consented and enrolled by the primary investigator. Once enrolled the subjects will be randomized to receive either two grams or three grams of cefazolin as prophylactic antibiotics to be given no more than 60 minutes prior to the start of the surgery.
Two adipose tissue samples will be obtained at the time of surgery. The first at the start after skin incision and the second at the end prior to closure of the skin. There will also be a separate IV placed at the start of the procedure from which three blood draws can be collected. These three samples will be obtained at the start of the surgery but after antibiotic administration, at the time of the first adipose collection, and at the time of the second adipose collection. The samples will then be stored at -80 degrees and shipped to David P. Nicolau's lab in Hartford, CT for the tissue and serum analysis.
While the subjects are in the hospital recovering from their surgery, a chart review will be performed to determine if there are any infections occuring post-operatively. A telephone survey will be conducted six to eight weeks postpartum again assessing for any infectious complications after the cesarean section.
Study Overview
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Rhode Island
-
Providence, Rhode Island, United States, 02905
- Women & Infants Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Obese - body mass index (BMI) calculated as weight (kg)/ [height (m2)]greater than or equal to 30 as determined at their first prenatal visit
- Gestational age of 37 0/7 weeks and greater
- Singleton Pregnancy
- Non-emergent cesarean section
Exclusion Criteria:
- Known cephalosporin allergy
- Severe allergy to penicillin making cephalosporin use a contraindication
- Exposure to antibiotics in the preceding 7 days
- Need for emergent cesarean section
- Multiple gestations
- Suspected chorioamnionitis
- Pre-gestational diabetes
- Chronic hypertension with evidence of end organ damage
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Two grams cefazolin
Two grams of cefazolin will be given by intravenous bolus zero to 60 minutes prior to the start of the cesarean section.
|
|
Active Comparator: Three grams cefazolin
Three grams of cefazolin will be given by intravenous bolus zero to 60 minutes prior to the start of the cesarean section.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adipose tissue concentration of cefazolin
Time Frame: At the start of the cesarean section and at the end of the cesarean section
|
Two separate two gram samples of adipose tissue will be removed from the subcutaneous tissue.
The first sample will be removed after skin incision, yet prior to fascial incision.
The second sample will be collected after fascial closure, yet prior to skin closure.
|
At the start of the cesarean section and at the end of the cesarean section
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Serum cefazolin concentrations
Time Frame: After antibiotic infusion, at the start of the cesarean section, and at the end of the cesarean section
|
Three separate intraoperative blood samples will be collected to evaluate the serum cefazolin concentrations.
The first sample will be collected after antibiotic administration, prior to the surgery start.
The next two samples will be collected coincidental to the time of adipose tissue collection.
The first after skin incision, yet prior to fascial incision.
The second after fascial closure, yet prior to skin closure.
|
After antibiotic infusion, at the start of the cesarean section, and at the end of the cesarean section
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Infectious morbidity
Time Frame: Participants will be followed for a duration of 6-8 weeks after the cesarean section
|
While in the hospital, chart reviews of the subject will be performed to identify any infectious complications.
A follow-up telephone survey will be conducted to assess for this outcome as well at six to eight weeks after surgery.
|
Participants will be followed for a duration of 6-8 weeks after the cesarean section
|
Collaborators and Investigators
Investigators
- Principal Investigator: Lindsay Maggio, MD, Women & Infant's Hospital
- Study Director: Brenna Anderson, MD, Women & Infants Hospital
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 13-0004
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Infection Prevention
-
Indiana University School of MedicineTerminatedInfection PreventionUnited States
-
Erasmus Medical CenterAmbu A/S; Maag Lever Darm StichtingCompletedEsophagogastroduodenoscopy | Gastroscopy | Equipment Design | Equipment Contamination / Prevention & Control | Cross Infection / Prevention & Control | Disposable Equipment | Infection Control / MethodsNorway, Netherlands
-
Montefiore Medical CenterMerck Sharp & Dohme LLCRecruiting
-
Klein, Jeffrey A., M.D.Completed
-
TaiMed Biologics Inc.Bill and Melinda Gates Foundation; Aaron Diamond AIDS Research CenterCompletedPrevention of Infection With HIV-1United States
-
Lindenhofgruppe AGCompletedStaphylococcus Aureus | Surgical Site Infection | Orthopaedic Surgery | PreventionSwitzerland
-
University of Alabama at BirminghamNational Cancer Institute (NCI); Merck Sharp & Dohme LLCCompletedCancer Survivor | Prevention of Human Papillomavirus InfectionUnited States
-
Balgrist University HospitalIndustry (Schülke & Mayr AG, Switzerland and Germany)RecruitingElective Surgery | High Risk | Prevention of Surgical Site Infections | Randomized-controlled TrialSwitzerland
-
Dr. Reddy's Laboratories LimitedGamaleya Research Institute of Epidemiology and Microbiology, Health Ministry... and other collaboratorsActive, not recruiting
-
Merck Sharp & Dohme LLCCompleted
Clinical Trials on Cefazolin
-
Abdul El-RabbanyRecruitingOrthognathic Surgical Site InfectionCanada
-
B. Braun Medical Inc.ParexelCompleted
-
University of Missouri-ColumbiaCompletedWounds and Injuries | Fractures, ClosedUnited States
-
B. Braun Medical Inc.Terminated
-
Aultman Health FoundationCompletedWound InfectionUnited States
-
Stanford UniversityCompletedPre-operative Prophylaxis With Vancomycin and Cefazolin in Pediatric Cardiovascular Surgery PatientsAortic Valve Disorder | Congenital Heart DiseasesUnited States
-
Phillip Brian SmithEunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedSepsis | PrematurityBrazil
-
Brigham and Women's HospitalCompletedAntibiotic ProphylaxisUnited States
-
Chang Gung Memorial HospitalNot yet recruitingPeriprosthetic Joint InfectionTaiwan